Silicosis and the Quartz Industry: A New Chapter or a Temporary Fix?

In September 2025, Business of Home published a sobering look at the artificial stone industry’s reckoning with accelerated silicosis—a deadly lung disease caused by inhaling nano-sized particles of crystalline silica and other toxins in traditional artificial stone. The article, “Is low-silica stone the path forward for the quartz industry?” spotlights the aftermath of a landmark $52 million verdict awarded to Gustavo Reyes Gonzalez, a 34-year-old artificial stone fabricator who required a double lung transplant after years of exposure to toxic crystalline silica and other toxins in artificial stone.

A Shift in Materials—But Is It Enough?

Following the Reyes Gonzalez case and Australia’s nationwide ban on artificial stone, major manufacturers like Caesarstone and Cosentino have introduced “low-“ and so-called “zero-silica” alternatives. According to their advertising, Caesarstone’s new “Icon” line contains less than 1% crystalline silica, while Cosentino’s Q0 surface boasts recycled content and claimed minimal silica levels.

As of this week, California’s Department of Public Health has recorded 391 silicosis cases and 22 deaths linked to artificial stone in California alone. The median age of diagnosis is just 46. These are not isolated incidents—they are a public health crisis.

New AI Tool May Improve Diagnosis of Pleural Effusion and Help Identify Pleural Cancer

An industrial robotic arm equipped with tools is working on a piece of artificial stone in a factory setting, surrounded by a dusty environment and wooden floor tiles.

“Death Sentences”: The Growing Artificial Stone Silicosis Crisis and the Fight Over Accountability

September 15, 2026

Diagram of a human ribcage showing mesothelioma in orange on the right lung’s lining, with a label pointing to the affected area.

VISTA Expression May Help Predict Survival Outcomes in Mesothelioma Patients Treated with Nivolumab

September 10, 2026

September 11, 2026

New AI Research Aims to Improve Pleural Effusion Diagnosis

A recent study by Song and colleagues, titled “Differential Diagnosis Model for Tuberculous and Malignant Pleural Effusion Combining U-Net Automatic Segmentation and Deep Learning”, demonstrates how artificial intelligence (AI) may help physicians distinguish between benign and malignant causes of pleural disease using advanced CT scan analysis. While the study focused on differentiating tuberculous pleural effusions from malignant pleural effusions, the findings illustrate a broader trend in pleural medicine that could ultimately benefit mesothelioma patients.

How Pleural Mesothelioma Leads to Fluid Buildup

Pleural mesothelioma develops in the thin membrane lining the lungs, known as the pleura. As the disease progresses, inflammation and tumor growth frequently interfere with normal fluid regulation within the pleural space. The result is often a malignant pleural effusion, which can cause significant breathing difficulties and may lead patients to seek medical attention before cancer is diagnosed.

Why Malignant Pleural Effusions Are Difficult to Diagnose

Unfortunately, malignant pleural effusions can resemble pleural effusions caused by other conditions. Imaging findings may overlap, symptoms are often nonspecific, and fluid analysis alone does not always provide a definitive diagnosis. Many patients undergo multiple diagnostic procedures before physicians can determine whether a pleural effusion is related to malignancy, infection, or another disease process.

A Key Early Clue for Physicians

For many mesothelioma patients, a pleural effusion is more than a symptom. It is often one of the first clinical signs that leads physicians to investigate the pleura for malignancy. Because early mesothelioma symptoms can be vague and nonspecific, identifying subtle clues within imaging studies may help clinicians recognize patients who require more extensive evaluation and specialized care.

Inside the Study: How Researchers Used AI to Analyze Pleural Effusions

Researchers evaluated 281 patients with confirmed pleural effusions, including cases related to both tuberculosis and cancer. Using chest CT scans, they developed an AI system that automatically identified abnormalities within the pleural space and analyzeds subtle imaging features that may be difficult for the human eye to detect. The technology relies on a deep-learning architecture called U-Net, which can automatically identify areas of interest onin medical images. The system then combines these imaging findings with clinical information to generate a prediction regarding the likely cause of the pleural effusion. The study found that the combined model performed exceptionally well, achieving a high degree of accuracy in distinguishing malignant pleural effusions from those caused by tuberculosis.

What the Findings Mean for Mesothelioma Patients

Although the study did not specifically focus on mesothelioma, its implications are highly relevant to people with suspected pleural cancers. Mesothelioma often presents with pleural abnormalities that can be difficult to interpret during the early stages of disease. Advanced AI tools may eventually help clinicians to recognize patterns associated with malignant pleural disease earlier and more consistently.

Faster identification of a potentially malignant pleural effusion could prompt earlier referrals to specialists, additional diagnostic testing, and more timely treatment planning. AI-based imaging analysis may also help physicians determine which patients should undergo invasive procedures such as thoracoscopy or pleural biopsy. Importantly, these technologies are not intended to replace pathologic diagnosis. Procedures such as biopsy remain the gold standard for confirming mesothelioma. However, AI may serve as a valuable decision-support tool that helps physicians navigate the complex diagnostic process more efficiently.

Pleural effusions remain one of the most common and challenging problems encountered in pleural medicine. For mesothelioma patients, they are often both a source of debilitating symptoms and an important clue that helps lead to diagnosis. Research such as the study by Song and colleagues suggests that artificial intelligence may become an increasingly valuable tool in evaluating pleural disease, helping clinicians distinguish malignant from nonmalignant causes of pleural effusion with greater accuracy.

As AI continues to advance, these technologies may play a growing role in the early detection and assessment of pleural cancers, including mesothelioma, potentially allowing patients to receive answers and appropriate care sooner.

Concerned About Mesothelioma or Asbestos Exposure?

If you or a loved one has been diagnosed with pleural mesothelioma, pleural effusion, or another asbestos-related disease, understanding your legal rights is important. Mesothelioma is often linked to occupational asbestos exposure that occurred decades before diagnosis.

Brayton Purcell LLP has represented individuals and families affected by asbestos-related diseases for decades. Our attorneys can help evaluate potential sources of exposure and explain the legal options that may be available to you and your family.

Contact Brayton Purcell LLP today for a free consultation to discuss your case and learn more about your rights.

Call (844) 768-0794

FAQs

1What is a pleural effusion?

A pleural effusion is an abnormal buildup of fluid between the lungs and the chest wall. Depending on the cause, it can lead to symptoms such as shortness of breath, chest pain, coughing, and fatigue.

2Is pleural effusion a sign of mesothelioma?

Not always. Pleural effusions can be caused by infections, heart failure, inflammatory conditions, and several types of cancer. However, pleural effusion is a common symptom of pleural mesothelioma and may be one of the earliest signs of the disease.

3How is pleural mesothelioma diagnosed?

Diagnosis typically involves imaging studies, including X-rays and CT scans, followed by procedures such as thoracentesis, pleural biopsy, or thoracoscopy. A biopsy remains the gold standard for confirming mesothelioma.

4Can artificial intelligence diagnose mesothelioma?

AI cannot independently diagnose mesothelioma. However, emerging AI tools may help physicians analyze medical imaging more efficiently, identify suspicious abnormalities, and support earlier evaluation of malignant pleural disease.

5What causes pleural mesothelioma?

Pleural mesothelioma is primarily caused by exposure to asbestos fibers. Many individuals diagnosed with mesothelioma were exposed to asbestos in workplaces such as shipyards, construction sites, power plants, refineries, manufacturing facilities, and military installations.

6What should I do if I have been diagnosed with mesothelioma?

Patients should seek treatment from physicians experienced in mesothelioma care and learn about all available medical and legal options. Consulting an attorney experienced in asbestos litigation can help determine whether compensation may be available.